Immune checkpoint inhibition increases antigen-specific T cell response in head and neck cancer

Abstract Therapeutic strategies which target immune checkpoint markers and enable the immune system to initiate immune responses against tumor cells represent a major advancement in cancer therapy. The response rate to anti-PD-1 checkpoint inhibition in head and neck cancer is about 20%, which under...

पूर्ण विवरण

ग्रंथसूची विवरण

मुख्य लेखकों:	Patrick J. Schuler, Franziska Oliveri, Lisa Puntigam, Klara Six, Carlotta Kaißer, Julia Maier, Simon Laban, Adrian von Witzleben, Cornelia Brunner, David A. C. Messerer, Hubert Schrezenmeier, Thomas K. Hoffmann, Marlies Goetz, Jochen Greiner
स्वरूप:	Artigo
भाषा:	Inglês
प्रकाशित:	Nature Portfolio 2026-02-01
श्रृंखला:	Scientific Reports
विषय:	Anti-LAG-3 (Lymphocyte activation gene 3) Anti-PD-1 (Programmed death-1, aPD-1) Anti-TIM-3 (T cell immunoglobulin and mucin-domain containing-3) Head and neck cancer (HNC) Immune checkpoints Melanoma-associated antigen (MAGE)
ऑनलाइन पहुंच:	https://doi.org/10.1038/s41598-026-38740-z
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!